

WHAT IS CLAIMED IS:

1. An anti-Immunoglobulin-like transcript-7 (ILT7) antibody comprising Complementarity-Determining Regions (CDRs) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 203, 204, 205, 208, 209, and 210, respectively.
2. The anti-ILT7 antibody of claims 1, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions comprise an amino acid sequence at least 95% identical to SEQ ID NO:202 and SEQ ID NO:207, respectively.
3. The anti-ILT7 antibody of claim 2, wherein the VH and VL regions comprise the amino acid sequence of SEQ ID NO:202 and SEQ ID NO:207, respectively.
4. The anti-ILT7 antibody according to claim 1, wherein the antibody comprises a heavy chain immunoglobulin constant domain selected from the group consisting of an IgA constant domain, an IgD constant domain, an IgE constant domain, an IgG1 constant domain, an IgG2 constant domain, an IgG3 constant domain, an IgG4 constant domain, and an IgM constant domain.
5. The anti-ILT7 antibody of claim 4, wherein the antibody comprises an IgG1 constant domain.
6. The anti-ILT7 antibody according to claim 1, wherein the antibody comprises a light chain immunoglobulin constant domain selected from the group consisting of an Ig kappa constant domain and an Ig lambda constant domain.
7. The anti-ILT7 antibody of claim 6, wherein the antibody comprises a lambda constant domain.
8. The anti-ILT7 antibody according to claim 1, wherein the antibody is a monoclonal antibody.

9. The anti-ILT7 antibody according to claim 1, wherein the antibody is a human, chimeric, or resurfaced antibody.
10. The anti-ILT7 antibody of claim 9, wherein the antibody is a human antibody.
11. The anti-ILT7 antibody according to claim 1, wherein the antibody is afucosylated.
12. The anti-ILT7 antibody according to claim 1, wherein the antibody specifically binds to human and cynomolgus ILT7.
13. An afucosylated, human, monoclonal anti-ILT7 antibody comprising:
 - i. Complementarity-Determining Regions (CDRs) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3;
 - ii. a human IgG1 constant domain; and
 - iii. a human lambda constant domain,wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:203, 204, 205, 208, 209, and 210, respectively.
14. A polynucleotide comprising a nucleic acid encoding the anti-ILT7 antibody of claim 1.
15. An isolated host cell comprising the polynucleotide of claim 14.
16. A method of producing an anti-ILT7 antibody, comprising culturing the isolated host cell of claim 15, and recovering said antibody.
17. A method for detecting ILT7 expression in a sample comprising (a) contacting said sample with the anti-ILT7 antibody of claim 1 and (b) detecting binding of said antibody in said sample.
18. A method for decreasing interferon (IFN)-alpha release from a plasmacytoid dendritic cell (pDC) comprising contacting a pDC with the anti-ILT7 antibody of claim 1.
19. The anti-ILT7 antibody of claim 1 for use in therapy.
20. Use of the anti-ILT7 antibody of claim 1 in the manufacture of a medicament for the treatment of an autoimmune disease, wherein the autoimmune disease is selected from the group consisting of: myositis, diabetes, Hashimoto's disease, autoimmune adrenal

insufficiency, pure red cell anemia, multiple sclerosis, rheumatoid carditis, systemic lupus erythematosus, psoriasis, rheumatoid arthritis, chronic inflammation, Sjogren's syndrome, polymyositis, dermatomyositis, inclusion body myositis, juvenile myositis, and scleroderma.

21. The use of claim 20, wherein the autoimmune disease is systemic lupus erythematosus.
22. An afucosylated IgG1 human monoclonal anti-ILT7 antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region comprises the amino acid of SEQ ID NO:202 and the light chain variable region comprises the amino acid of SEQ ID NO:207.
23. The anti-ILT7 antibody of claim 22, wherein the antibody comprises a human IgG1 constant domain; and a human lambda constant domain.
24. A pharmaceutical composition comprising afucosylated IgG1 human monoclonal anti-ILT7 antibody of claim 22.